company background image
SNOA

Sonoma Pharmaceuticals NasdaqCM:SNOA Stock Report

Last Price

US$2.27

Market Cap

US$7.0m

7D

6.6%

1Y

-58.4%

Updated

06 Oct, 2022

Data

Company Financials
SNOA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SNOA Stock Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally.

Sonoma Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sonoma Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.27
52 Week HighUS$7.20
52 Week LowUS$2.06
Beta1.04
1 Month Change-18.14%
3 Month Change-23.57%
1 Year Change-58.43%
3 Year Change-54.96%
5 Year Change-94.67%
Change since IPO-99.91%

Recent News & Updates

Aug 11

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Sonoma Pharmaceuticals press release (NASDAQ:SNOA): Q1 GAAP EPS of -$0.29. Revenue of $3.99M (+8.4% Y/Y).

Shareholder Returns

SNOAUS PharmaceuticalsUS Market
7D6.6%-0.2%3.3%
1Y-58.4%3.6%-20.4%

Return vs Industry: SNOA underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: SNOA underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is SNOA's price volatile compared to industry and market?
SNOA volatility
SNOA Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: SNOA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SNOA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199912Amy Tromblyhttps://www.sonomapharma.com

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds.

Sonoma Pharmaceuticals Fundamentals Summary

How do Sonoma Pharmaceuticals's earnings and revenue compare to its market cap?
SNOA fundamental statistics
Market CapUS$7.04m
Earnings (TTM)-US$4.87m
Revenue (TTM)US$12.93m

0.5x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SNOA income statement (TTM)
RevenueUS$12.93m
Cost of RevenueUS$8.94m
Gross ProfitUS$3.99m
Other ExpensesUS$8.86m
Earnings-US$4.87m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.57
Gross Margin30.83%
Net Profit Margin-37.71%
Debt/Equity Ratio6.0%

How did SNOA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SNOA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNOA?

Other financial metrics that can be useful for relative valuation.

SNOA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.2x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SNOA's PS Ratio compare to its peers?

SNOA PS Ratio vs Peers
The above table shows the PS ratio for SNOA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.2x
CPHI China Pharma Holdings
0.9xn/aUS$7.2m
EMMA Emmaus Life Sciences
0.4x15.4%US$5.9m
NBY NovaBay Pharmaceuticals
0.7x37.3%US$6.9m
GPFT Grapefruit USA
26.7xn/aUS$4.9m
SNOA Sonoma Pharmaceuticals
0.5xn/aUS$7.0m

Price-To-Sales vs Peers: SNOA is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (7.2x).


Price to Earnings Ratio vs Industry

How does SNOA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: SNOA is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is SNOA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNOA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SNOA's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SNOA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNOA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNOA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Sonoma Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sonoma Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Sonoma Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


25.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SNOA is currently unprofitable.

Growing Profit Margin: SNOA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNOA is unprofitable, but has reduced losses over the past 5 years at a rate of 25.1% per year.

Accelerating Growth: Unable to compare SNOA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNOA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: SNOA has a negative Return on Equity (-61.25%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Sonoma Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SNOA's short term assets ($14.8M) exceed its short term liabilities ($4.9M).

Long Term Liabilities: SNOA's short term assets ($14.8M) exceed its long term liabilities ($4.3M).


Debt to Equity History and Analysis

Debt Level: SNOA has more cash than its total debt.

Reducing Debt: SNOA's debt to equity ratio has increased from 0.7% to 6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNOA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNOA has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.7% each year.


Discover healthy companies

Dividend

What is Sonoma Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Sonoma Pharmaceuticals Dividend Yield vs Market
How does Sonoma Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Sonoma Pharmaceuticals)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Sonoma Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate SNOA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNOA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNOA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNOA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SNOA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Amy Trombly (54 yo)

0.25yr

Tenure

US$621,000

Compensation

Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 25, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...


CEO Compensation Analysis

Amy Trombly's Compensation vs Sonoma Pharmaceuticals Earnings
How has Amy Trombly's remuneration changed compared to Sonoma Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$5m

Dec 31 2021n/an/a

-US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021US$621kUS$300k

-US$5m

Dec 31 2020n/an/a

-US$3m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020US$386kUS$153k

-US$4m

Compensation vs Market: Insufficient data to establish whether Amy's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Amy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SNOA's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: SNOA's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of SNOA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders16,8020.5%
Institutions193,0686.2%
General Public2,891,06793.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.2%.


Top Shareholders

Top 22 shareholders own 6.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
2.44%
Renaissance Technologies LLC
75,767$172.0k25.51%no data
1.19%
Geode Capital Management, LLC
36,878$83.7k0%no data
1.1%
The Vanguard Group, Inc.
34,014$77.2k23.28%no data
0.83%
Citadel Advisors LLC
25,677$58.3k0%no data
0.27%
Dimensional Fund Advisors LP
8,275$18.8k-1.02%no data
0.24%
Bank of America Corporation, Asset Management Arm
7,426$16.9k16777.27%no data
0.19%
Jay Birnbaum
5,739$13.0k0%no data
0.17%
John McLaughlin
5,414$12.3k0%no data
0.16%
Sharon Surrey-Barbari
4,824$11.0k0%no data
0.093%
BlackRock, Inc.
2,875$6.5k0%no data
0.027%
Bruce Thornton
825$1.9k0%no data
0.022%
UBS Asset Management
670$1.5k-82.05%no data
0.017%
Tower Research Capital LLC
523$1.2k-61.66%no data
0.016%
U.S. Bancorp Asset Management, Inc.
500$1.1k0%no data
0.0053%
Securities America Advisors, Inc.
166$376.80%no data
0.0028%
Morgan Stanley, Investment Banking and Brokerage Investments
86$195.2-12.24%no data
0.0025%
Rockefeller & Co. LLC
77$174.80%no data
0.0021%
Allworth Financial, L.P.
65$147.60%no data
0.001%
Gradient Investments, LLC
31$70.40%no data
0.00068%
Wells Fargo & Company, Private Banking and Investment Banking Arm
21$47.710.53%no data
0.00042%
Northern Oak Capital Management, Inc.
13$29.50%no data
0.00013%
Strategic Advisers LLC
4$9.10%no data

Company Information

Sonoma Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sonoma Pharmaceuticals, Inc.
  • Ticker: SNOA
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.039m
  • Shares outstanding: 3.10m
  • Website: https://www.sonomapharma.com

Number of Employees


Location

  • Sonoma Pharmaceuticals, Inc.
  • 645 Molly Lane
  • Suite 150
  • Woodstock
  • Georgia
  • 30189
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNOANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2007
O8Z3DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2007

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Earnings2022/06/30
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.